At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade. With the FDA approval of Gilead's ...

Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages and can eventually destroy the bile ducts of the liver. Researchers ...

There isn’t a cure for PBC, but the right treatment plan can slow its progress and boost your quality of life as you live with it.

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term ...

Primary biliary cirrhosis (PBC) is a chronic, cholestatic liver disease characterized by progressive destruction of intrahepatic bile ducts, resulting in chronic cholestasis, portal inflammation ...

GSK has announced positive headline results of its ongoing global Phase III clinical trial GLISTEN, which is evaluating the use of linerixibat in the treatment of adult patients with cholestatic ...

Expert Rev Mol Diagn. 2012;12(1):65-74. The NE is composed of three morphologically and functionally interconnected structures: a double bilayer nuclear membrane enclosing the perinuclear space ...